Zacks Research Issues Optimistic Forecast for HALO Earnings

Key Points

• Zacks Research raised Halozyme’s FY2026 EPS estimate to $8.24 from $7.56, above the current consensus of $7.75. The firm also projected continued earnings growth through FY2028.
• Halozyme’s latest quarterly results exceeded expectations, with EPS of $2.28 versus the $1.79 consensus and revenue of $481 million, up 47.7% year over year. Management guided to FY2026 EPS of $8.65–$9.00.
• Analyst sentiment remains favorable, with nine Buy ratings, three Holds and one Sell, producing a “Moderate Buy” consensus rating and an average price target of $91.20. Shares opened at $109.66, near their 12-month high.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Investment analysts at Zacks Research boosted their FY2026 earnings estimates for shares of Halozyme Therapeutics in a report issued on Thursday, August 27th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $8.24 per share for the year, up from their prior estimate of $7.56. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $7.75 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q4 2026 earnings at $2.53 EPS, Q1 2027 earnings at $1.78 EPS, Q4 2027 earnings at $3.03 EPS, FY2027 earnings at $9.01 EPS, Q1 2028 earnings at $2.05 EPS, Q2 2028 earnings at $2.71 EPS and FY2028 earnings at $10.06 EPS.

HALO has been the subject of a number of other reports. Wall Street Zen raised Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Citizens Jmp increased their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a report on Friday, August 7th. HC Wainwright restated a "buy" rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. UBS Group reissued a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, TD Cowen lifted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $91.20.

Halozyme Therapeutics Stock Up 1.8%

NASDAQ:HALO opened at $109.66 on Thursday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a 12-month low of $61.22 and a 12-month high of $109.76. The stock's fifty day simple moving average is $89.29 and its 200-day simple moving average is $75.36. The firm has a market capitalization of $12.45 billion, a P/E ratio of 32.73, a P/E/G ratio of 0.43 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the previous year, the firm posted $1.54 earnings per share. Halozyme Therapeutics's revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,478 shares of company stock valued at $3,076,604 over the last 90 days. 2.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. MidFirst Bank bought a new position in shares of Halozyme Therapeutics in the second quarter valued at $27,000. Larson Financial Group LLC grew its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 343 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $28,000. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analysts raised near- and medium-term forecasts: Zacks Research increased its FY2026 EPS estimate to $8.24 from $7.56, above the current consensus of $7.75. Estimates were also raised for Q4 2026, Q1 2027, FY2027, Q1 2028 and Q2 2028. These revisions suggest improving expectations for Halozyme’s royalty and drug-delivery business.
• Positive Sentiment: Buy rating reaffirmed: HC Wainwright maintained a “buy” rating and a $115 price target, implying additional upside from the stock’s recent trading level. The endorsement provides further support for the bullish outlook.
• Positive Sentiment: Momentum and fundamentals remain strong: Halozyme recently reported quarterly EPS of $2.28, well ahead of the $1.79 analyst consensus, while revenue rose 47.7% year over year to $481 million. The company’s FY2026 guidance calls for EPS of $8.65 to $9.00. Halozyme Therapeutics Hits New 1-Year High
• Neutral Sentiment: Investor conferences scheduled: Chief Executive Officer Helen Torley and Chief Financial Officer Darren Snellgrove will participate in upcoming investor conferences and meetings. The events could provide updates on ENHANZE and Halozyme’s expanded drug-delivery portfolio, but no new financial information was announced. Halozyme to Participate at Upcoming Investor Conferences
• Negative Sentiment: One longer-term estimate was trimmed: Zacks lowered its FY2028 EPS forecast to $10.06 from $10.21. However, the reduction was modest and was partly offset by higher estimates for several intervening quarters.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source